Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature.
| Image |  |
|---|---|
| Description | scientific article |
| Author/s |
author: Firat Yalniz Yucel Erbilgin Nükhet Tüzüner Tugrul Elverdi Ahmet Emre Eskazan Muhlis Cem Ar |
| Publication date | October 9, 2017 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |